Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Trial Identifier:	QHD00023
Sponsor:	Sanofi Pasteur, a Sanofi Company
Start Date:	November 2020
Primary Completion Date:	February 2021
Study Completion Date:	February 2021
Condition:	Influenza Immunisation; Healthy Volunteers

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Stay informed about new Trial Results Summaries with our email notification service

Country	Location
TAIWAN, PROVINCE OF CHINA	Taichung, TAIWAN, PROVINCE OF CHINA, 40447
TAIWAN, PROVINCE OF CHINA	Taipei, TAIWAN, PROVINCE OF CHINA, 112
TAIWAN, PROVINCE OF CHINA	Taipei, TAIWAN, PROVINCE OF CHINA, 100
TAIWAN, PROVINCE OF CHINA	Taoyuan, TAIWAN, PROVINCE OF CHINA, 333